Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
TipRanks on MSN15h
Desert Metals Ltd. Releases Interim Financial Report for 2024Desert Metals Ltd. ( ($AU:DM1) ) has provided an announcement. Desert Metals Ltd. has released its interim financial report for the half year ...
Stockhead on MSN5h
High Voltage: Congo’s cobalt cuts cause price spike as China scrambles for supplyA DRC cobalt export ban may only impact prices in the short term, but could point to a broader price control strategy to come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback